Trevi Therapeutics(TRVI)2025-03-18 20:10Financial Position - As of December 31, 2024, Trevi Therapeutics estimates its cash, cash equivalents, and marketable securities to be $107.6 million[4]. - The company emphasizes that the cash estimate is preliminary and subject to change, pending audit and review[5]. - The company has not yet filed audited financial results for the preliminary cash estimate[5]. - The report indicates that the company is not an emerging growth company under the relevant regulations[3]. Clinical Trials - The Phase 2a RIVER trial for refractory chronic cough has completed patient visits, with topline results expected in Q1 2025[7]. - The Phase 2b CORAL trial in idiopathic pulmonary fibrosis is approximately 80% enrolled, with topline results anticipated in the first half of 2025[8]. - The original sample size for the CORAL trial remains reaffirmed at 160 patients following a positive outcome from a sample size re-estimation analysis[8]. - Forward-looking statements include expectations for clinical trials and cash runway, highlighting inherent risks and uncertainties[9]. Events and Communications - The company is participating in the 14th Annual LifeSci Partners Corporate Access Event from January 13 to 15, 2025[4]. - The press release detailing these updates was issued on January 8, 2025[10].